The burden of psoriasis necessitates the exploration of broad therapeutic options, with a particular focus on cAMP targeted by PDE4 inhibitors to reduce the inflammatory cytokine secretion associated with psoriasis as an expanding avenue for treatment. Here, PDE4A is linked to psoriasis.